Combined HAT/EZH2 modulation leads to cancer-selective cell death

Abstract : Epigenetic alterations have been associated with both pathogenesis and progression of cancer. By screening of library compounds, we identified a novel hybrid epi-drug MC2884, a HAT/EZH2 inhibitor, able to induce bona fide cancer-selective cell death in both solid and hematological cancers in vitro, ex vivo and in vivo xenograft models. Anticancer action was due to an epigenome modulation by H3K27me3, H3K27ac, H3K9/14ac decrease, and to caspase-dependent apoptosis induction. MC2884 triggered mitochondrial pathway apoptosis by up-regulation of cleaved-BID, and strong down-regulation of BCL2. Even aggressive models of cancer, such as p53-/- or TET2-/- cells, responded to MC2884, suggesting MC2884 therapeutic potential also for the therapy of TP53 or TET2-deficient human cancers. MC2884 induced massive apoptosis in ex vivo human primary leukemia blasts with poor prognosis in vivo, by targeting BCL2 expression. MC2884-treatment reduced acetylation of the BCL2 promoter at higher level than combined p300 and EZH2 inhibition. This suggests a key role for BCL-2 reduction in potentiating responsiveness, also in combination therapy with BCL2 inhibitors. Finally, we identified both the mechanism of MC2884 action as well as a potential therapeutic scheme of its use. Altogether, this provides proof of concept for the use of epi-drugs coupled with epigenome analyses to 'personalize' precision medicine.
Document type :
Journal articles
Complete list of metadatas

Cited literature [43 references]  Display  Hide  Download

https://hal.archives-ouvertes.fr/hal-01873834
Contributor : Laurence Naiglin <>
Submitted on : Monday, September 17, 2018 - 3:20:48 PM
Last modification on : Wednesday, July 10, 2019 - 10:02:06 AM
Long-term archiving on : Tuesday, December 18, 2018 - 2:16:00 PM

File

25428-1004878-5-PB.pdf
Publication funded by an institution

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Collections

Citation

Francesca Petraglia, Abhishek Singh, Vincenzo Carafa, Angela Nebbioso, Mariarosaria Conte, et al.. Combined HAT/EZH2 modulation leads to cancer-selective cell death. Oncotarget, Impact journals, 2018, 9 (39), pp.25630-25646. ⟨10.18632/oncotarget.25428⟩. ⟨hal-01873834⟩

Share

Metrics

Record views

317

Files downloads

34